Jonathan R Brody
Overview
Explore the profile of Jonathan R Brody including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
5179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Finan J, Guo Y, Bartlett A, Reyer M, Hawthorne K, Haerr M, et al.
bioRxiv
. 2025 Feb;
PMID: 39975239
Pancreatic ductal adenocarcinoma (PDAC) tumors contain chaotic vasculature that limits immune surveillance and promotes early events in the metastatic cascade. However, current antiangiogenic therapies have failed in PDAC, and thus,...
2.
Link J, Eng J, Pelz C, MacPherson-Hawthorne K, Worth P, Sivagnanam S, et al.
Nat Cancer
. 2025 Jan;
6(1):123-144.
PMID: 39789181
Patients with metastatic pancreatic ductal adenocarcinoma survive longer if disease spreads to the lung but not the liver. Here we generated overlapping, multi-omic datasets to identify molecular and cellular features...
3.
Arneson-Wissink P, Pelz K, Worley B, Mendez H, Pham P, McCarthy G, et al.
bioRxiv
. 2025 Jan;
PMID: 39763867
Background: Cachexia is defined by chronic loss of fat and muscle, is a frequent complication of pancreatic ductal adenocarcinoma (PDAC), and negatively impacts patient outcomes. Nutritional supplementation cannot fully reverse...
4.
Finan J, Guo Y, Goodyear S, Brody J
Unknown
. 2024 Dec;
1:e2400050.
PMID: 39735733
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths with a 5-year survival rate of 13%. Surgical resection remains the only curative option as systemic therapies offer...
5.
6.
Finan J, Di Niro R, Park S, Jeong K, Hedberg M, Smith A, et al.
Cancer Biol Ther
. 2024 Nov;
25(1):2421584.
PMID: 39513592
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease soon to become the second leading cause of cancer deaths in the US. Beside surgery, current therapies have narrow clinical benefits with...
7.
8.
Lopez C, Kardosh A, Chen E, Pegna G, Guimaraes A, Foster B, et al.
Future Oncol
. 2024 Oct;
20(37):2915-2925.
PMID: 39378065
Asparagine synthetase (ASNS) catalyzes the biosynthesis of asparagine from aspartate and glutamine. Cells lacking ASNS, however, are auxotrophic for asparagine. Use of L-asparaginase to promote asparagine starvation in solid tumors...
9.
Brody J, Klein A
Cancer Res
. 2024 Sep;
84(18):2941-2943.
PMID: 39279378
In 1996, Goggins and colleagues demonstrated the importance of germline BRCA2 pathogenic variants in the development of apparently sporadic pancreatic ductal adenocarcinoma (PDAC). Previously, the group identified homozygous deletion of...
10.
Zarei M, Hajihassani O, Hue J, Loftus A, Graor H, Nakazzi F, et al.
Cancer Res
. 2024 Jun;
84(18):3072-3085.
PMID: 38843355
Pancreatic ductal adenocarcinoma (PDAC) is associated with a 5-year overall survival rate of just 13%, and development of chemotherapy resistance is nearly universal. PDAC cells overexpress wild-type isocitrate dehydrogenase 1...